Approval · Notice of Compliance 23717 · 2020
RUPALL: Notice of Compliance 23717
Issued June 4, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23717
- Date
- June 4, 2020
- Company
- Medexus Pharmaceuticals Inc.Bolton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Merger/Buy-out
Products in this notice
Medicinal ingredients
- RUPATADINE FUMARATE 10 MG per TAB
- RUPATADINE FUMARATE 1 MG per ML